Results 11 to 20 of about 41,247 (202)
Sex Differences in Response to Viral Vector Vaccines-Implications for Future Vaccine Design. [PDF]
Immunol RevABSTRACT Vaccination represents one of the most impactful public health achievements, preventing 3.5 to 5 million deaths annually according to estimates of the World Health Organization. Yet, recent outbreaks of emerging and reemerging infectious diseases highlight the need for rapid and strategic vaccine development using vaccine platforms ...
Grewe I, Zoran T, Addo MM.
europepmc +2 more sources
PLoS ONE, 2023 Introduction Decisions about prevention of and response to Ebola outbreaks require an understanding of the macroeconomic implications of these interventions.
Laura T. R. Morrison +9 more
doaj +2 more sources
The Evolution of Medical Countermeasures for Ebola Virus Disease: Lessons Learned and Next Steps
Vaccines, 2022 The Ebola virus disease outbreak that occurred in Western Africa from 2013–2016, and subsequent smaller but increasingly frequent outbreaks of Ebola virus disease in recent years, spurred an unprecedented effort to develop and deploy effective vaccines ...
Ian Crozier +10 more
doaj +1 more source
The Current Landscape and Future Prospects of Vaccine Manufacturing in Africa: Challenges, Innovations, and Opportunities: A Narrative Review. [PDF]
Health Sci RepABSTRACT Background and Aims Africa has significant challenges in meeting its vaccination needs, including inadequate manufacturing capacity, infrastructure deficiencies, a scarcity of experienced personnel, regulatory hurdles, restricted access to technology and intellectual property.
Chandipwisa C +3 more
europepmc +2 more sources
Identification of Novel Adjuvants for Ebola Virus-Like Particle Vaccine
Vaccines, 2020 Ebola virus disease is a severe disease, often fatal, with a mortality rate of up to 90%. Presently, effective treatment and safe prevention options for Ebola virus disease are not available. Therefore, there is an urgent need to develop control measures
Huapeng Feng +7 more
doaj +1 more source
Ebola vaccination – Authors' reply [PDF]
The Lancet, 2015 2016-03-19T19:12 ...
Department of Biostatistics, University of Florida, Gainesville, FL, USA ( host institution ) +5 more
openaire +3 more sources
Development of a TB vaccine trial site in Africa and lessons from the Ebola experience
BMC Public Health, 2020 Tuberculosis is the deadliest infection of our time. In contrast, about 11,000 people died of Ebola between 2014 and 2016. Despite this manifest difference in mortality, there is now a vaccine licensed in the United States and by the European Medicines ...
G. Kaguthi +13 more
doaj +1 more source
Vaccines against Ebola virus [PDF]
Vaccine, 2018 We have just witnessed the largest and most devastating outbreak of Ebola virus disease, which highlighted the urgent need for development of an efficacious vaccine that could be used to curtail future outbreaks. Prior to 2014, there had been limited impetus worldwide to develop a vaccine since the virus was first discovered in 1976.
Venkatraman, N +3 more
openaire +3 more sources
A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa. [PDF]
, 2017 The 2014-2015 Ebola epidemic affected several African countries, claiming more than 11,000 lives and leaving thousands with ongoing sequelae. Safe and effective vaccines could prevent or limit future outbreaks.
Agnandji, ST +17 more
core +2 more sources
Cell Reports, 2018 Summary: Comparative immune response profiling is important for selecting next-generation vaccines. We comprehensively evaluated the antibody responses from a panel of nine respiratory vaccines against Ebola virus (EBOV) derived from human and avian ...
Michelle Meyer +7 more
doaj +1 more source